What is HC Wainwright’s Estimate for ALDX FY2027 Earnings?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Equities research analysts at HC Wainwright decreased their FY2027 EPS estimates for shares of Aldeyra Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will earn $0.08 per share for the year, down from their previous estimate of $0.11. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share.

Separately, BTIG Research restated a “buy” rating and set a $9.00 price target on shares of Aldeyra Therapeutics in a research report on Monday, November 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.50.

Aldeyra Therapeutics Trading Down 10.6%

Shares of Aldeyra Therapeutics stock opened at $4.65 on Thursday. The stock has a market capitalization of $279.84 million, a price-to-earnings ratio of -8.16 and a beta of 0.97. The firm’s 50-day moving average price is $5.02 and its two-hundred day moving average price is $5.17. Aldeyra Therapeutics has a 1-year low of $1.14 and a 1-year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC boosted its holdings in Aldeyra Therapeutics by 456.3% in the first quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company’s stock valued at $2,257,000 after acquiring an additional 321,992 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Aldeyra Therapeutics during the 1st quarter valued at about $218,000. Jane Street Group LLC bought a new position in shares of Aldeyra Therapeutics in the 1st quarter valued at about $1,024,000. Acadian Asset Management LLC boosted its stake in shares of Aldeyra Therapeutics by 7,402.7% in the 1st quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company’s stock valued at $551,000 after purchasing an additional 94,681 shares during the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $57,000. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.